An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Drugmakers were offering a form of semaglutide that you put under the tongue to UK medical practices, even though the company that makes the approved injectable versions had raised concerns. In short: clinics were being approached to use or sell a sublingual (under-the-tongue) version of semaglutide, and the maker of the standard product warned this was problematic. Semaglutide is the active ingredient in widely known medicines for diabetes and weight loss, like Ozempic and Wegovy. It’s a man-made copy of a natural gut hormone that helps control blood sugar and signals fullness to the brain. The approved versions are injections. A “sublingual” form would be a liquid or tablet placed under the tongue to be absorbed through the mouth instead of injected. The report suggests companies were promoting this sublingual semaglutide to UK practices even though Novo Nordisk, the company behind the approved injected drugs, had raised safety or legitimacy concerns. The story doesn’t say this new form has gone through the same full clinical trials or official approvals. It also doesn’t provide large, high-quality study results showing that the under-the-tongue version works as well or is as safe as the injections. So right now the evidence behind these offers looks limited or unsettled. Why this matters is practical. If a sublingual version worked and were proven safe, it could be easier for people who dislike needles to take the medicine. That could expand access to treatments for diabetes or weight management. But because the established maker has expressed worries, and because medicines should be tested carefully, patients and practices should be cautious about switching to or endorsing an unproven format. There are clear caveats. If the sublingual form hasn’t gone through regulatory approval (which the headline implies may be a concern), its quality, dose accuracy and safety aren’t guaranteed. Side effects known for semaglutide — like nausea, vomiting, and rare but serious risks such as pancreatitis — may still occur. People with certain medical conditions, pregnant people, and children may be at particular risk and should not use unapproved formulations. Until regulators and large trials verify a new form, doctors should be wary of adopting it. Bottom line: clinics were being pitched an under-the-tongue semaglutide product despite the original maker’s warnings, but there’s not yet clear, approved evidence that this alternative form is safe or effective.
Source: Pharmaceutical Technology